Inozyme Pharma, Inc.
INZY · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $58 | $174 | $331 | $273 |
| - Cash | $26 | $21 | $25 | $15 |
| + Debt | $47 | $47 | $47 | $47 |
| Enterprise Value | $80 | $200 | $353 | $305 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$26 | -$25 | -$23 | -$25 |
| % Margin | – | – | – | – |
| Net Income | -$28 | -$27 | -$25 | -$27 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.44 | -0.43 | -0.39 | -0.44 |
| % Growth | -2.3% | -10.3% | 11.4% | – |
| Operating Cash Flow | -$29 | -$19 | -$25 | -$24 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$29 | -$19 | -$25 | -$24 |